Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2021-08-23 00:00:00 ET · period of report 2021-08-19 · accession 0001209191-21-052881 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-08-23 | 2021-08-19 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | P - Purchase | $195.65 | +10.0K | 73.8K | +16% | +$1.96M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-19 | P | A | 5,757 | $195.14 | 69,511 | D | — | — | (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. (F1) Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50). |
| 2 | Common | Common Stock | 2021-08-19 | P | A | 4,243 | $196.34 | 73,754 | D | — | — | (F3) Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58). (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. |